Core Framework & Diagram Major Breakthroughs in Immunology History
July 24, 20261 Min Read Major Failures in Immunology History
July 24, 2026From cowpox inoculation to CAR-T, humanity took 230 years
—— Each breakthrough was a qualitative leap in understanding the immune system.
I. Jenner and cowpox: the first step from folk observation to scientific practice (1796)
On May 14, 1796, English country doctor Edward Jenner injected cowpox pus into eight-year-old James Phipps's arm. A few weeks later, he inoculated Phipps with real smallpox — Phipps didn't fall ill. This experiment is considered one of the most important medical experiments in history, founding the practice of vaccination (from Latin 'vacca,' meaning 'cow'). Jenner's insight came from a folk observation: milkmaids rarely got smallpox. He reasoned that milkmaids, through contact with cowpox (a much less toxic related virus), had gained protection against smallpox. His contribution wasn't only doing this experiment, but systematically transforming folk wisdom into reproducible medical practice, and driving widespread adoption of this technology. Jenner in 1796 had no idea that viruses existed (viruses wouldn't be discovered until the late nineteenth century), didn't know about immune cells, didn't know about antibodies. He only knew 'this works.' This is the earliest characteristic of immunological breakthroughs: practice preceding theory, observation preceding mechanism.
2. Pasteur and attenuated vaccines: from accident to system (1879–1885)
Louis Pasteur was the key figure who elevated immunology from 'folk craft' to 'experimental science.' In 1879, a classic laboratory accident changed history: his assistant forgot to process chicken cholera bacterial cultures before the holiday, and after exposure to air the bacteria's virulence weakened. Infecting chickens with this old culture left them sick but alive; infecting those recovered chickens with fresh lethal cultures, they still survived — while uninfected chickens died. Pasteur realized that specifically reducing pathogens' virulence could preserve immunogenicity while reducing pathogenicity. He systematically applied this principle to anthrax (1881 public demonstration proving vaccine efficacy before media and public) and rabies (1885, vaccinating nine-year-old Joseph Meister after a rabid dog bite, the boy survived). Pasteur's contribution was systematizing Jenner's accidental discovery into an actively designable principle: find attenuation methods, manufacture vaccines. Without modern immunological knowledge, through rigorous experimental design and extraordinary intuition, he founded modern vaccinology's basic methodology.
3. Monoclonal antibody technology: immunology's industrial revolution (1975)
In 1975, Georges Köhler and César Milstein at the UK Medical Research Council published a paper describing how to fuse antibody-producing B cells with myeloma cells to create 'hybridoma cells' — capable of both producing specific antibodies and proliferating indefinitely. This technology's impact extended far beyond immunology itself. At the research level, monoclonal antibodies enabled scientists to precisely identify and track any cell type or molecule — CD4, CD8, CD19, and other immune cell markers we know today were all discovered and defined using monoclonal antibodies. At the clinical level, monoclonal antibodies became modern biopharmaceutical industry's pillar: among today's globally top-selling drugs, large numbers are therapeutic monoclonal antibodies — including PD-1 inhibitors for tumor immunotherapy, TNF inhibitors (adalimumab) for rheumatoid arthritis, and neutralizing antibodies for COVID-19. Köhler and Milstein received the 1984 Nobel Prize. Worth noting: they deliberately chose not to patent this technology — believing scientific knowledge should be public property. This decision opened the technology to the whole world, accelerating its spread and application.
4. MHC restriction: the secret of how T cells 'see' (1974)
In 1974, Peter Doherty and Rolf Zinkernagel at John Curtin School of Medical Research in Australia answered a question that had puzzled immunologists for years: how do cytotoxic T cells (CTL) recognize and kill virus-infected cells? They found that CTL, when recognizing target cells, don't just recognize the viral antigen itself but simultaneously recognize the target cell's MHC-I molecules. Specifically, the TCR simultaneously binds both MHC-I molecules and the viral peptide presented on them — neither alone is sufficient. This is called 'MHC restriction.' In other words, CTL can only kill cells carrying 'their own' MHC type while simultaneously infected with virus; they can't directly attack free viral particles, nor attack infected cells from individuals with different MHC types. This discovery explained the nature of organ transplant rejection, explained why T cells can't directly attack free virus, and established modern complete understanding of adaptive immunity recognition mechanisms. Doherty and Zinkernagel jointly received the 1996 Nobel Prize.
5. mRNA vaccines: 2021's miracle, thirty years of accumulation
The COVID mRNA vaccines deployed globally in 2021 are often described as 'the fastest-developed vaccines in human history' — only eleven months from genome sequence publication to approval. But behind this speed was thirty years of difficult foundational research by Karikó, Weissman, Cullis, and others in mRNA technology and lipid nanoparticles. Karikó's story is particularly moving. In the early 1990s she began researching mRNA therapy, believing directly injecting chemically modified mRNA into the human body could induce therapeutic protein expression. But in the following decade, almost every funding application she submitted was rejected. The University of Pennsylvania canceled her tenure, demoting her to regular researcher. She kept working after demotion, collaborating with Weissman to complete key work on nucleoside-modified mRNA. In 2021, BioNTech/Pfizer and Moderna's COVID mRNA vaccines directly adopted her and Weissman's nucleoside modification technology — vaccines ultimately administered to over three billion people. In 2023, they jointly received the Nobel Prize. The mRNA vaccine platform's significance extends far beyond COVID — it's being used to develop HIV vaccines, broad-spectrum influenza vaccines, RSV vaccines, personalized tumor vaccines, and gene replacement therapies.
6. Common features of these breakthroughs: accident, persistence, and tools ready
Reviewing the ten greatest immunology breakthroughs, several common features stand out. First, many breakthroughs came from accidents — Pasteur's attenuated vaccine, the discovery of penicillin (Fleming noticed fungal contamination in bacterial culture dishes), ABO blood groups (Landsteiner trying to understand why mixing blood from different people caused clotting). Accidents themselves aren't breakthroughs, but the ability to stop before accidents, observe carefully, and ask 'why?' is the core quality of scientific breakthroughs. Second, almost all breakthroughs required persistence beyond the ordinary — Jenner's cowpox experiment met ridicule from the medical establishment and religious opposition; Karikó's mRNA research received no recognition for twenty years; Matzinger's danger signal theory was rejected by colleagues. Real breakthroughs often walk ahead of consensus, meaning breakthrough-makers must persist in isolated environments long enough. Third, every breakthrough depended on technological tools unique to its era — monoclonal antibody technology made CD4/CD8 discovery possible; gene knockout technology made immune memory mechanism research possible; single-cell sequencing technology made immune cell subpopulation discovery possible; lipid nanoparticle technology made mRNA vaccines possible. Technology maturation is always quietly ready before scientists can see the next question clearly.
Frequently Asked Questions